ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients-Reference-Cited by-同舟云学术

ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients

Published:2021-06-22 Issue:14 Volume:10 Page:4948-4956
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Patil Anand¹,Shriyan Bharati¹,Mehta Parsshava¹,Patil Mrudula¹,Gurjar Murari¹,Nookala Manjunath¹²,Patil Vijay²³,Joshi Amit²³,Noronha Vanita²³,Prabhash Kumar²³^ORCID,Gota Vikram¹²^ORCID

Affiliation:

1. Department of Clinical Pharmacology Advanced Centre for Treatment, Research and Education in Cancer Tata Memorial Centre Mumbai India

2. Homi Bhabha National Institute Mumbai India

3. Department of Medical Oncology Tata Memorial Hospital Mumbai India

Funder

Indian Council of Medical Research

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4026

Reference24 articles.

1. Taxotere®(docetaxel).Injection concentrate 20 mg/mL and 80 mg/4 mL: 77.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020449orig1s075.pdf

2. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

3. Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol

4. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

5. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients;Current Drug Metabolism;2024-08-16

2. Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients;Annals of Translational Medicine;2022-06

3. Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients;Current Opinion in Oncology;2022-03-09